[HTML][HTML] Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM) …
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
direct on-tumor and immunomodulatory mechanism of action. Daratumumab induces rapid …
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 …
In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of
disease progression or death by 63% and increased the overall response rate (ORR) versus …
disease progression or death by 63% and increased the overall response rate (ORR) versus …
[HTML][HTML] Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd …
Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …
direct on-tumor and immunomodulatory mechanism of action, is approved in combination …
Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and …
8025 Background: Daratumumab (D) is a human CD38-targeting mAb that significantly
prolongs progression-free survival (PFS) when added to standard-of-care regimens in …
prolongs progression-free survival (PFS) when added to standard-of-care regimens in …
Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial
MA Dimopoulos, A Oriol, H Nahi… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …
[HTML][HTML] Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients …
Introduction: Daratumumab is a human monoclonal antibody targeting CD38 that
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …
demonstrated superior efficacy in combination with lenalidomide and dexamethasone (DRd) …
[HTML][HTML] Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone …
Introduction: Daratumumab is a human, CD38-targeted, IgGκ monoclonal antibody with both
direct on-tumor and immunomodulatory mechanisms of action. In the phase 3 POLLUX …
direct on-tumor and immunomodulatory mechanisms of action. In the phase 3 POLLUX …
Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly …
Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as …
with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as …
[HTML][HTML] Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM) …
Introduction: Daratumumab (D) is a human monoclonal antibody targeting CD38 that is
approved as a monotherapy and in combination with standard of care regimens for patients …
approved as a monotherapy and in combination with standard of care regimens for patients …
[HTML][HTML] Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma …
P Moreau, JL Kaufman, HJ Sutherland, M Lalancette… - Blood, 2016 - Elsevier
Introduction: Daratumumab is an anti-CD38 IgGκ monoclonal antibody that has been
combined successfully with lenalidomide and dexamethasone. The combination of …
combined successfully with lenalidomide and dexamethasone. The combination of …